CTOs on the Move

Complexa Inc

www.complexarx.com

 
Complexa is a clinical stage biopharmaceutical company focused on transforming the treatment of fibrosis and inflammation-associated orphan diseases. Leveraging its differentiated endogenous nitrated fatty acid cell signaling technology, Complexa is advancing a platform of agents which target fibrosis and inflammation across multiple orphan disease indications.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.complexarx.com
  • 170 North Radnor Chester Road Suite 350
    Radnor, PA USA
  • Phone: 323.602.1096

Executives

Name Title Contact Details

Funding

Complexa Inc raised $62M on 07/26/2017

Similar Companies

St. Mary's Janesville Hospital

St. Mary's Janesville Hospital is a Janesville, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zuni Technologies Inc

Zuni Technologies Inc is a Zuni, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aspira Women`s Health

Aspira Women`s Health Inc. (formerly known as Vermillion, Inc. Nasdaq: VRML) is transforming women`s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1®plus combines our FDA-cleared products OVA1® and OVERA® to detect the risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiXSM testing offers both targeted and a more comprehensive genetic testing options with a gynecologic focus. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment.

New Century Pharmaceuticals

New Century Pharmaceuticals is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Erasca

Our mission at Erasca is embedded in our name: To erase cancer. Energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology`s hardest problems. We have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals. In addition to our initial programs for undisclosed cancer targets, we seek to expand our pipeline through partnerships with academic scientists and biopharmaceutical companies who have revealed potential new mechanisms for precision oncology. Importantly, Erasca isn`t tied to one form of drug or any singular approach to treating cancer. By keeping an open mind about what is possible, we believe we will achieve the greatest results for patients everywhere.